MXPA03011793A - Formulaciones de interferon. - Google Patents

Formulaciones de interferon.

Info

Publication number
MXPA03011793A
MXPA03011793A MXPA03011793A MXPA03011793A MXPA03011793A MX PA03011793 A MXPA03011793 A MX PA03011793A MX PA03011793 A MXPA03011793 A MX PA03011793A MX PA03011793 A MXPA03011793 A MX PA03011793A MX PA03011793 A MXPA03011793 A MX PA03011793A
Authority
MX
Mexico
Prior art keywords
interferon
compositions
interferon formulations
relates
formulations
Prior art date
Application number
MXPA03011793A
Other languages
English (en)
Spanish (es)
Inventor
Drustrup Jorn
Original Assignee
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd filed Critical Maxygen Holdings Ltd
Publication of MXPA03011793A publication Critical patent/MXPA03011793A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MXPA03011793A 2001-06-29 2002-06-28 Formulaciones de interferon. MXPA03011793A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200101040 2001-06-29
DKPA200101277 2001-08-30
DKPA200200257 2002-02-19
PCT/DK2002/000444 WO2003002152A2 (en) 2001-06-29 2002-06-28 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins

Publications (1)

Publication Number Publication Date
MXPA03011793A true MXPA03011793A (es) 2004-04-02

Family

ID=27222516

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011793A MXPA03011793A (es) 2001-06-29 2002-06-28 Formulaciones de interferon.

Country Status (7)

Country Link
EP (1) EP1414498A2 (https=)
JP (1) JP2004522803A (https=)
CN (1) CN1522159A (https=)
CA (1) CA2452364A1 (https=)
MX (1) MXPA03011793A (https=)
RU (1) RU2004102500A (https=)
WO (1) WO2003002152A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
JP5207590B2 (ja) 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
CA2547822A1 (en) * 2003-12-11 2005-06-30 Ares Trading S.A. Stabilized interferon liquid formulations
CA2567309A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
CN1984674A (zh) * 2004-06-07 2007-06-20 纳斯泰克制药公司 不含蛋白质或多肽类稳定剂的干扰素β鼻内制剂
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
WO2007022799A1 (en) * 2005-08-26 2007-03-01 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
EP1991679A2 (fr) * 2006-03-08 2008-11-19 Biomethodes Variants de l'interferon- gamma humain (ifngamma)
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
WO2008076933A2 (en) * 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
JP5681485B2 (ja) 2007-04-27 2015-03-11 サイデックス・ファーマシューティカルズ・インコーポレイテッド クロピドグレルおよびスルホアルキルエーテルシクロデキストリンを含有する製剤ならびに使用方法
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
JP5563475B2 (ja) 2007-12-20 2014-07-30 メルク セローノ ソシエテ アノニム Ｐｅｇインターフェロン−ベータ製剤
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
MX2011005051A (es) * 2008-11-17 2011-06-01 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas.
CA2761455C (en) 2009-05-13 2018-06-12 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
RU2482871C2 (ru) * 2010-06-07 2013-05-27 Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") Композиция для лечения вирусных заболеваний животных
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US10344204B2 (en) 2015-04-09 2019-07-09 Diversion Technologies, LLC Gas diverter for well and reservoir stimulation
US10012064B2 (en) 2015-04-09 2018-07-03 Highlands Natural Resources, Plc Gas diverter for well and reservoir stimulation
CN115400220A (zh) 2015-12-30 2022-11-29 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂
US10982520B2 (en) 2016-04-27 2021-04-20 Highland Natural Resources, PLC Gas diverter for well and reservoir stimulation
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2017194783A1 (en) * 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
WO2020028275A1 (en) * 2018-07-30 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists
CN111358938B (zh) * 2020-03-30 2023-08-11 温州肯恩大学(Wenzhou-KeanUniversity) 人干扰素-ε与干扰素-γ组合药及用途
CN113797317B (zh) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 一种组合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6133248A (en) * 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof

Also Published As

Publication number Publication date
CA2452364A1 (en) 2003-01-09
CN1522159A (zh) 2004-08-18
JP2004522803A (ja) 2004-07-29
WO2003002152A3 (en) 2003-05-01
RU2004102500A (ru) 2005-04-10
WO2003002152A2 (en) 2003-01-09
EP1414498A2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
MXPA03011793A (es) Formulaciones de interferon.
YU27403A (sh) Postupak za pripremanje preparata u obliku praha
WO2001058412A3 (de) Extrakte von rückständen aus der weinherstellung
WO2004043363A8 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
MY142354A (en) Acidic insulin preparations having improved stability
WO2002076404A3 (en) Fatty alcohol drug conjugates
CY2016024I2 (el) ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ
HUS1800013I1 (hu) Cladribine tartalmú orális gyógyászati készítmény
MXPA04005517A (es) Composiciones farmaceuticas bajo forma de gel o solucion a base de dihidrotestosterona, su metodo de preparacion y sus usos.
AU2002232819A1 (en) Methods for the production of multimeric proteins, and related compositions
WO2001066565A3 (en) In vivo production of cyclic peptides
TWI317736B (en) Methods for the production of redox proteins and heteromultimeric-protein-complexes, and related compositions related applications
WO2001005355A3 (en) Formulations for il-11
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2003086272A3 (en) Ultrapure transferrin for pharmaceutical compositions
WO2002096936A3 (en) Daptomycin and related analogs in crystalline form, their preparation and use
IL174479A (en) The derivatives of myastrin, pharmaceutical preparations containing them and their uses
DE50213839D1 (de) Dünnflüssige, sprühbare w/o emulsionen
MXPA03011128A (es) Composicion de sabor y fragancia.
PL1677818T3 (pl) Stabilne kompozycje wodne zawierające G-CSF
SG142165A1 (en) Biologically active peptides
AU2003236764A1 (en) Fragrance composition
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
WO2006023465A8 (en) Polyethylene glycol-peptide copper complexes and compositions and methods related thereto